Multifunctional nanoparticles to improve treatment of human glioblastoma The long-term objective of this research is to develop novel therapeutic approaches to improve the clinical outcome of adult patients with glioblastoma multiforme (GBM), the most common and lethal human primary brain tumor. Recent clinical trials have demonstrated that administration of the methylating agent temozolomide (TMZ) during post-operative therapy significantly increases survival of GBM patients. Although TMZ in combination with radiation is now the contemporary standard of care for GBMs, the majority of GBMs are not responsive due to the resistance mediated by O6-methylguanine-DNA methyltransferase (MGMT), a DNA repair protein that limits the radiosensitizing and cytotoxic effects of TMZ. Recent studies from our group and others suggest that the resistance of GBMs to TMZ can be overcome by ablating MGMT activity with DNA repair inhibitors. However, the clinical utility of DNA repair inhibitors have been hindered by their poor pharmacokinetics such as poor permeability of the blood-brain barrier (BBB), a short half-life, and bone marrow producing deleterious side-effects. We propose to develop a multifunctional nanoparticle (NP) that can deliver DNA inhibitors specifically to GBM cells to circumvent treatment-resistance and treatment-limiting systemic toxicity. Our multidisciplinary team has developed prototype NPs consisting of an iron oxide core surrounded by a shell of a biodegradable polymer of polyethylene glycol grafted chitosan (PEG-chitosan). The core-shell structure is conjugated with the near-infrared fluorophore Cy5.5 and the targeting ligand chlorotoxin (CTX). Each element of this NP system confers a property that makes it an excellent candidate as an image-guided drug delivery vehicle. In this study, inhibitors are covalently attached to the outer shell of the NP tht is crosslinked by disulfide linkage and can be rapidly degraded by glutathione-mediated reduction in cytosol of target cells to release the payload but not in blood. The project includes the following Specific Aims: (1) Fabrication and characterization of inhibitor derivatized NPs; (2) Assessment of therapeutic effects of NPs on human GBM cells, and in vivo toxicity and BBB permeation of NPs; (3) Study of therapeutic efficacy of NPs in an orthotopic GBM xenograft model of human GBM. Our NPs incorporate features that facilitate drug loading, protect drug during transport, penetrate the BBB, facilitate rapid intracellular release, and confer tumor specificity. Moreover, each component material of the NP is biocompatible and assumes multiple functions. This strategy combines the advances in forefront research of GBM cancer biology with advanced nanotechnology in tumor imaging and therapeutics to circumvent the resistance to treatment. Successful completion of the proposed work may produce a novel therapeutic agent that can be readily brought to clinical trial as our NP is expressly designed to improve the efficacy of the current standard of care for GBM. The expanded health relevance of this research is that the NPs with BBB penetration ability may also facilitate the delivery of therapeutic agents to brain metastases from a variety of tumors.

Public Health Relevance

We propose to develop a multifunctional nanoparticle that can deliver DNA repair inhibitors specifically to glioblastoma multiforme (GBM) cells to circumvent the therapy resistance and systemic toxicity. This novel strategy combines the advances in forefront research of GBM cancer biology with advanced nanotechnology in tumor imaging and therapeutics to address the current limitations in treatment of GBMs. Successful completion of the proposed work will produce a novel therapeutic agent ready to be brought to clinical trials in patients with GBMs.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Developmental Therapeutics Study Section (DT)
Program Officer
Ogunbiyi, Peter
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
Engineering (All Types)
Schools of Engineering
United States
Zip Code
Wang, Hui; Mu, Qingxin; Revia, Richard et al. (2018) Iron oxide-carbon core-shell nanoparticles for dual-modal imaging-guided photothermal therapy. J Control Release 289:70-78
Mu, Qingxin; Wang, Hui; Zhang, Miqin (2017) Nanoparticles for imaging and treatment of metastatic breast cancer. Expert Opin Drug Deliv 14:123-136
Stephen, Zachary R; Gebhart, Rachel N; Jeon, Mike et al. (2017) pH-Sensitive O6-Benzylguanosine Polymer Modified Magnetic Nanoparticles for Treatment of Glioblastomas. Bioconjug Chem 28:194-202
Chiarelli, Peter A; Revia, Richard A; Stephen, Zachary R et al. (2017) Nanoparticle Biokinetics in Mice and Nonhuman Primates. ACS Nano 11:9514-9524
Wang, Hui; Wang, Kui; Mu, Qingxin et al. (2017) Mesoporous carbon nanoshells for high hydrophobic drug loading, multimodal optical imaging, controlled drug release, and synergistic therapy. Nanoscale 9:1434-1442
Wang, Hui; Revia, Richard; Wang, Kui et al. (2017) Paramagnetic Properties of Metal-Free Boron-Doped Graphene Quantum Dots and Their Application for Safe Magnetic Resonance Imaging. Adv Mater 29:
Kievit, Forrest M; Wang, Kui; Ozawa, Tatsuya et al. (2017) Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma. Nanomedicine 13:2131-2139
Wang, Hui; Mu, Qingxin; Revia, Richard et al. (2017) Chitosan-Gated Magnetic-Responsive Nanocarrier for Dual-Modal Optical Imaging, Switchable Drug Release, and Synergistic Therapy. Adv Healthc Mater 6:
Wang, Kui; Kievit, Forrest M; Zhang, Miqin (2016) Nanoparticles for cancer gene therapy: Recent advances, challenges, and strategies. Pharmacol Res 114:56-66
Wang, Hui; Wang, Kui; Tian, Bowei et al. (2016) Preloading of Hydrophobic Anticancer Drug into Multifunctional Nanocarrier for Multimodal Imaging, NIR-Responsive Drug Release, and Synergistic Therapy. Small 12:6388-6397

Showing the most recent 10 out of 22 publications